Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

No payment amount, production volume or timetable was disclosed for the collaboration.

Rhea-AI Summary

Codexis (CDXS) signed an agreement with an unnamed siRNA drug developer to explore stereo-defined fragment synthesis using its ECO Synthesis platform.

Codexis will use an enzymatic process to make the fragments, which the developer will join into a final two-strand molecule. The collaboration will compare those fragments with ones made by conventional solid-phase synthesis, evaluating purity, product quality and how well they join. The developer will use the results to assess potential use in future clinical development programs. Codexis previously demonstrated full-length siRNA synthesis with control over phosphorothioate stereochemistry using its StereoSelect capability at TIDES USA 2026.

Argus 15 min delay 1 alert

+8.76% vs previous close $1.44 last price 0.0x rel. volume Open Argus

Details

Market move: CDXS +8.76% vs previous close. siRNA manufacturing partnership

$1.25 $1.44 Day Range

$157.21M Market Cap

On Sep 28, the day this news came out, the latest delayed price for CDXS is 8.76% above the previous close. The latest delayed price is $1.44.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

sirna, phosphorothioate stereochemistry, solid-phase oligonucleotide synthesis

3 terms

sirna medical

"agreement with a pioneering siRNA drug innovator"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

phosphorothioate stereochemistry technical

"precise control of phosphorothioate stereochemistry"

Phosphorothioate stereochemistry describes the three-dimensional arrangement at a modified link in synthetic DNA/RNA drugs where one oxygen is swapped for sulfur, producing mirror-image forms like left- and right-hand versions of a glove. Those mirror-image forms can alter a drug’s stability, activity and side-effect profile and complicate manufacturing and quality control, so they affect development risk, regulatory review, production cost and commercial reliability for investors.

solid-phase oligonucleotide synthesis technical

"conventional solid-phase oligonucleotide synthesis (SPOS)"

A laboratory method that builds short strands of DNA or RNA one base at a time on a solid support, such as a resin bead or glass plate, using chemical steps that add and protect each nucleotide until the full sequence is complete. It matters to investors because this manufacturing technique determines how quickly, cheaply, and reliably companies can produce therapeutic oligonucleotides and diagnostic probes; think of it as assembling a precise chain of letters on a fixed workbench, where process control, scale and quality affect product supply and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis^® Manufacturing Platform.

The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelect^SM, a capability of ECO Synthesis.

Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality.

The collaboration will also compare enzymatically synthesized fragments with conventional solid-phase oligonucleotide synthesis (SPOS), evaluating purity, product quality, and ligation performance. The results will allow the innovator to assess the technology's potential for future clinical development programs.

Alison Moore, PhD., President and CEO at Codexis, said: “This agreement is an important next step in bringing our latest ECO Synthesis capabilities to a customer. Working with a pioneer in the siRNA field offers an exciting opportunity to demonstrate how ECO Synthesis can deliver stereochemical control, which may offer both superior product quality and therapeutic performance to an innovator’s pipeline over assets produced using traditional solid phase chemistry methods.”

Codexis continues to advance the ECO Synthesis Manufacturing Platform as part of its strategy to industrialize scalable manufacturing solutions for complex oligonucleotide therapeutics.

About Codexis, Inc.

Codexis^® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis^® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the Company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Georgia Erbez
+1 (650) 421-8100
ir@codexis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Codexis produce under its ECO Synthesis agreement with an siRNA developer?

Codexis will produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The developer will receive the fragments and join them into a final two-strand molecule through ligation.